BRIEF-Medicinova Announces Additional Positive Results About Effects Of MN-001 On Serum Lipid Panel In Type 2 Diabetes And NAFLD Patients Presented At IDF 2022 Congress
Reuters
Dec 07, 2022
Dec 6 (Reuters) - MediciNova Inc :
* MEDICINOVA ANNOUNCES ADDITIONAL POSITIVE RESULTS REGARDING THE EFFECTS OF MN-001 (TIPELUKAST) ON SERUM LIPID PANEL IN TYPE 2 DIABETES AND NAFLD PATIENTS PRESENTED AT IDF 2022 CONGRESS, THE ANNUAL MEETING OF THE INTERNATIONAL DIABETES FEDERATION
* MEDICINOVA - MN-001 SIGNIFICANTLY REDUCED SERUM TRIGLYCERIDES IN PARTICIPANTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND HYPERTRIGLYCERIDEMIA
* MEDICINOVA INC - COMPARED TO SUBJECTS WITHOUT T2DM, T2DM GROUP SHOWED A GREATER REDUCTION IN SERUM TRIGLYCERIDE LEVELS AT WEEK 8
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.